Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Trends, Share & Forecast Analysis 2026–2034

The global Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is witnessing rapid growth as healthcare systems increasingly focus on the early diagnosis and effective management of chronic liver diseases. Rising cases of obesity, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD) are driving demand for reliable, non-invasive diagnostic tools capable of identifying NASH at earlier stages. Biomarkers have emerged as valuable tools for detecting liver inflammation, fibrosis, and disease progression without relying solely on invasive liver biopsies. Continued advances in biomarker discovery, molecular diagnostics, artificial intelligence (AI), and precision medicine are expected to reshape the future of NASH diagnosis and patient management. Market Size (2025): USD 1.76 Billion Market Size (2026): USD 2.16 Billion CAGR (2026–2034): 22.8% Forecast Year: 2034 Projected Market Size (2034): USD 11.15 Billion Dominant Region: North America Fastest Growing Region: Europe Market Overview Non-alcoholic steatohepatitis (NASH) biomarkers are biological indicators used to diagnose, monitor, and assess disease progression in patients with NASH, an advanced form of non-alcoholic fatty liver disease. These biomarkers provide clinicians with critical insights into liver health, enabling earlier intervention and improved disease management while reducing dependence on invasive liver biopsy procedures. Growing awareness of metabolic liver diseases, expanding clinical research activities, and the increasing availability of advanced diagnostic technologies are supporting widespread adoption of biomarker-based testing. As pharmaceutical companies continue developing targeted therapies for NASH, biomarker-driven diagnostics are becoming increasingly important for patient identification, treatment monitoring, and clinical trial enrollment. Growth Drivers The rapidly increasing prevalence of NASH is one of the strongest factors driving market expansion. Rising obesity rates, sedentary lifestyles, diabetes, and metabolic syndrome have significantly increased the global burden of liver disease, creating substantial demand for accurate and accessible diagnostic solutions. Healthcare providers are increasingly recognizing the importance of early diagnosis to prevent progression to advanced fibrosis, cirrhosis, and liver failure. Non-invasive biomarkers offer a practical solution for identifying at-risk patients, monitoring disease progression, and improving long-term clinical outcomes. Growing investments in chronic liver disease research and expanding pharmaceutical pipelines for NASH therapies are also contributing to increased demand for biomarker-based diagnostics. Challenges The lack of standardized diagnostic criteria and universally accepted biomarker panels remains a significant challenge for the market. Multiple diagnostic approaches currently exist, resulting in variations in clinical interpretation and diagnostic consistency across healthcare settings. Differences in biomarker panels, imaging techniques, and clinical assessment protocols may create uncertainty for healthcare providers when evaluating patients. Continued collaboration among researchers, diagnostic companies, regulatory authorities, and healthcare organizations will be essential to establish standardized testing protocols and improve clinical adoption. Opportunities Ongoing advances in biomarker research are creating significant opportunities for the market. Researchers continue identifying novel genetic, proteomic, metabolomic, and molecular biomarkers capable of improving diagnostic accuracy and enabling earlier disease detection. Artificial intelligence and machine learning technologies are further accelerating biomarker discovery by analyzing complex clinical datasets to identify predictive disease patterns. The integration of AI with genomic, proteomic, and metabolomic data is expected to improve patient stratification, personalize treatment strategies, and enhance clinical decision-making. As precision medicine continues evolving, advanced biomarker platforms are expected to play a central role in the diagnosis and management of metabolic liver diseases. Segment Analysis Based on type, the serum biomarkers segment accounts for the largest market share due to its convenience, non-invasive nature, and widespread clinical adoption. Blood-based biomarker testing enables clinicians to assess liver health efficiently while distinguishing between simple steatosis and more advanced stages of NASH. The continued development of novel serum biomarkers, including apolipoproteins, adipokines, inflammatory markers, and metabolic indicators, is expected to further strengthen segment growth throughout the forecast period. Apoptosis biomarkers are also gaining increasing attention because of their ability to detect liver cell death and differentiate NASH from uncomplicated fatty liver disease, supporting more accurate diagnosis. By end use, the pharmaceutical and contract research organization (CRO) segment dominates the market. Biomarkers play a critical role in clinical trials, patient selection, drug development, and therapeutic monitoring, making them indispensable for pharmaceutical companies developing next-generation NASH therapies. Diagnostic laboratories are also expected to witness strong growth as awareness of chronic liver diseases increases and demand for advanced diagnostic services expands worldwide. Regional Analysis North America remains the largest market for NASH biomarkers due to its advanced healthcare infrastructure, high diagnosis rates, robust research ecosystem, and favorable regulatory environment. Strong investments in biomarker research, widespread clinical trial activity, and increasing adoption of non-invasive diagnostic tests continue supporting regional market leadership. The region also benefits from growing availability of commercially approved diagnostic tests and expanding collaborations among pharmaceutical companies, diagnostic laboratories, and healthcare providers. Europe is projected to register healthy growth during the forecast period. Increasing awareness of metabolic liver diseases, expanding pharmaceutical research activities, and supportive clinical practice guidelines are encouraging broader adoption of biomarker-based diagnostics across the region. Asia Pacific is expected to experience the fastest long-term expansion as obesity rates, diabetes prevalence, and lifestyle-related liver diseases continue increasing. Rising healthcare investments, improving diagnostic capabilities, and growing awareness among healthcare professionals are creating favorable conditions for market growth across China, India, Japan, and other regional economies. Latin America, the Middle East, and Africa are also expected to witness gradual market development as healthcare access improves and demand for early liver disease diagnosis continues to increase. Competitive Landscape The global NASH biomarkers market is highly dynamic, with biotechnology companies, diagnostic laboratories, pharmaceutical organizations, and healthcare technology providers investing heavily in biomarker discovery, molecular diagnostics, and precision medicine. Strategic collaborations, product innovation, clinical research, and regulatory approvals continue shaping the competitive environment. Key companies operating in the market include: Genfit Prometheus Laboratories Siemens Medical Solutions USA Inc. BioPredictive Quest Diagnostics AstraZeneca Exalenz Bioscience Ltd. Laboratory Corporation of America Holdings (Labcorp) Pfizer Inc. Bristol-Myers Squibb Company Recent Developments In May 2025, GENFIT expanded its biomarker development programs for metabolic liver diseases by advancing non-invasive diagnostic approaches designed to improve identification and monitoring of patients with non-alcoholic steatohepatitis. Labcorp expanded its liver disease testing capabilities in June 2025 by introducing enhanced biomarker-based diagnostic services supporting both clinical research and patient assessment for metabolic dysfunction-associated steatohepatitis (MASH/NASH). In July 2025, Thermo Fisher Scientific strengthened its biomarker discovery capabilities through advancements in proteomics and molecular analysis technologies supporting liver disease diagnostic development. OWL Metabolomics expanded its metabolomics-based diagnostic portfolio in September 2025 by enhancing non-invasive biomarker testing solutions for liver disease assessment and NASH evaluation. Click Here to Access the Comprehensive Report:https://straitsresearch.com/report/non-alcoholic-steatohepatitis-biomarkers-market Future Outlook The global non-alcoholic steatohepatitis biomarkers market is expected to experience exceptional growth through 2034, driven by the increasing burden of metabolic liver diseases, continuous innovation in biomarker research, and growing adoption of non-invasive diagnostic technologies. Advances in genomics, proteomics, metabolomics, artificial intelligence, and precision medicine will continue transforming NASH diagnosis while supporting personalized treatment strategies and accelerating therapeutic development. As healthcare providers increasingly emphasize early intervention and disease monitoring, biomarker-based diagnostics are expected to become a cornerstone of future liver disease management. About Straits Research Straits Research is a leading global market intelligence and consulting company specializing in market research, business intelligence, strategic consulting, and industry analysis across multiple sectors. The company provides comprehensive market forecasts, competitive intelligence, customized research solutions, and actionable insights that help organizations identify emerging opportunities, make informed decisions, and achieve sustainable business growth.